DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

MRI Homepage

Coon Memorial brings MR in-house with Canon Medical's Vantage Titan 1.5 T scanner Thomas Berryman, lead MR tech at Coon Memorial Hospital discusses the benefits that have come with trading out their mobile trailer for a fixed unit

More than half of patients who undergo diagnostic imaging feel anxious: survey A need for greater face-to-face interactions and consultations

Cool Pair Plus acquires Tripwire from Simplexable for MR monitoring Bringing new capabilities to the daVinci Remote Magnet Monitoring System

Teenager dies tragically during general anesthetic for MR exam A reminder that MR safety is as complex as the patients admitted for imaging

Imaging Biometrics files patent for 'contrast-free' MR software May save on exam time and cost, while avoiding use of GBCAs

Cam Conklin Innovatus Imaging appoints new vice president of global sales and marketing

The surprising link between MR helium leaks and iPhone shutdowns Invaluable insights from one system specialist's MR ramp-up

Researchers combine MR with augmented reality to enhance cardio procedures Using Microsoft HoloLens to view myocardial scarring

Siemens launches RT Pro edition of MAGNETOM Sola at ASTRO MR system assists in radiation therapy treatment planning

New Philips MR and CT scanners debut at ASTRO CT system, Big Bore RT, and Ingenia MR-RT take aim at radiotherapy outcomes

FDA to require gadolinium retention label warnings

by Thomas Dworetzky , Contributing Reporter
In the ongoing discussion over gadolinium-based contrast agents, the U.S. Food and Drug Administration (FDA) has now issued a safety communication.

It will require “a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs,” the agency said in a statement.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



No direct link to adverse health impacts have been found in those with normally functioning kidneys, noted the agency, explaining that “we have concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.”

That said, the added review and talks with the Medical Imaging Drugs Advisory Committee, has led to changes designed to highlight retention issues with MR imaging using GBCA.

These include a new Medication Guide for patients to be read prior to getting a GBCA, as well as requiring makers to perform further animal and human studies over its safety.

The kidneys usually clear the agents, but trace amounts have been found in the body. For those with a higher risk of retention, such as patients who may need multiple doses, those who are pregnant, children and those with inflammatory conditions, the agency advises care, but stressed, “do not avoid or defer necessary GBCA MR scans.”

For those at risk, the FDA pointed out that linear GBCAs “result in more retention and retention for a longer time than macrocyclic GBCAs,” and to give them accordingly.

As a result of its review, stated Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, “we recommend that health care professionals consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk, such as those who may require repeat GBCA MR scans to monitor a chronic condition."

In specific, it stated that body levels of gadolinium are highest with Omniscan (gadodiamide) or OptiMARK (gadoversetamide) compared with Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine), or MultiHance (gadobenate dimeglumine). Gadolinium levels are lowest when using Dotarem (gadoterate meglumine), Gadavist (gadobutrol), and ProHance (gadoteridol) – and levels are similar for these agents.

Although the health impact of gadolinium retention has yet to be established, the agency noted that “we are continuing to assess the health effects of gadolinium retention in the body and will update the public when new information becomes available.”
  Pages: 1 - 2 >>

MRI Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED